Cogent Biosciences, Inc. (COGT)
NASDAQ: COGT · IEX Real-Time Price · USD
8.61
-0.14 (-1.60%)
At close: Jul 19, 2024, 4:00 PM
8.56
-0.05 (-0.58%)
Pre-market: Jul 20, 2024, 9:28 AM EDT

Cogent Biosciences Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year Ending
TTM Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019 2018 - 2015
Revenue
00007.8722.5
Upgrade
Revenue Growth (YoY)
-----65.02%131.14%
Upgrade
Gross Profit
00007.8722.5
Upgrade
Selling, General & Admin
36.8834.3826.2119.6417.4210.97
Upgrade
Research & Development
190.42173.76121.6355.9125.7443.71
Upgrade
Other Operating Expenses
000046.910
Upgrade
Operating Expenses
227.3208.13147.8475.5590.0754.68
Upgrade
Operating Income
-227.3-208.13-147.84-75.55-82.2-32.18
Upgrade
Other Expense / Income
-15.13-15.72-7.6-3.28-7.39-0.35
Upgrade
Pretax Income
-212.17-192.41-140.24-72.27-74.81-31.83
Upgrade
Net Income
-212.17-192.41-140.24-72.27-74.81-31.83
Upgrade
Preferred Dividends
0000104.40
Upgrade
Net Income Common
-212.17-192.41-140.24-72.27-179.21-31.83
Upgrade
Shares Outstanding (Basic)
95805939118
Upgrade
Shares Outstanding (Diluted)
95805939118
Upgrade
Shares Change
34.03%35.61%51.66%249.52%45.42%22.43%
Upgrade
EPS (Basic)
-2.48-2.42-2.39-1.87-16.17-4.18
Upgrade
EPS (Diluted)
-2.48-2.42-2.39-1.87-16.17-4.18
Upgrade
Free Cash Flow
-168.4-156.42-125.5-60.48-35.53-41.34
Upgrade
Free Cash Flow Per Share
-1.78-1.96-2.14-1.56-3.21-5.43
Upgrade
Gross Margin
----100.00%100.00%
Upgrade
Operating Margin
-----1044.33%-143.02%
Upgrade
Profit Margin
-----2276.81%-141.49%
Upgrade
Free Cash Flow Margin
-----451.40%-183.75%
Upgrade
EBITDA
-208.24-188.82-134.36-70.28-74.09-30.54
Upgrade
EBITDA Margin
-----941.28%-135.74%
Upgrade
Depreciation & Amortization
3.933.595.881.990.721.29
Upgrade
EBIT
-212.17-192.41-140.24-72.27-74.81-31.83
Upgrade
EBIT Margin
-----950.43%-141.49%
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).